Enriched clinical annotations |
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. |
Clinical annotation |
Category |
P-value |
Hits |
Hits(%) |
Module hits in category |
Arrays in annotation |
Arrays |
Liver tissue (Liver cancer*) |
Liver cancer* |
6.2e-20 |
58 |
32.7 |
177 |
187 |
1945 |
Liver tissue, cancer or cell line (Liver cancer*) |
Liver cancer* |
1.1e-18 |
58 |
32.7 |
177 |
197 |
1945 |
Hepatitis infected liver (Liver cancer*) |
Liver cancer* |
1.6e-18 |
51 |
28.8 |
177 |
156 |
1945 |
Acute leukemia (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Cancer and cell line (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Cancer (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Hematologic cancer and cell line (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Hematologic cancer (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Hematologic samples and cell lines (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Leukemia (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Leukemia or leukemia cell line (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Monocytes (Leukemia*) |
Leukemia* |
2.2e-17 |
74 |
17.7 |
416 |
141 |
1945 |
Cancer and cell line (Various tumors*) |
Various tumors* |
2.5e-14 |
57 |
13.7 |
416 |
105 |
1945 |
Cancer (Various tumors*) |
Various tumors* |
2.5e-14 |
57 |
13.7 |
416 |
105 |
1945 |
Hematologic cancer and cell line (Stimulated PBMC) |
Stimulated PBMC |
6.1e-14 |
19 |
79.1 |
24 |
30 |
182 |
Macrophages (Stimulated PBMC) |
Stimulated PBMC |
6.1e-14 |
19 |
79.1 |
24 |
30 |
182 |
Hematologic samples and cell lines (B lymphoma) |
B lymphoma |
1.7e-13 |
58 |
86.5 |
67 |
121 |
245 |
Lymphoma (B lymphoma) |
B lymphoma |
6.4e-13 |
45 |
67.1 |
67 |
77 |
245 |
Non-tumor liver tissue (Liver cancer) |
Liver cancer |
5.8e-12 |
43 |
74.1 |
58 |
76 |
207 |
Acute lymphocytic leukemia (Leukemia) |
Leukemia |
7.1e-10 |
72 |
87.8 |
82 |
99 |
149 |
Cancer and cell line (Liver cancer) |
Liver cancer |
7.2e-10 |
42 |
97.6 |
43 |
126 |
207 |
Lymphocytes (Leukemia) |
Leukemia |
7.0e-09 |
64 |
86.4 |
74 |
91 |
141 |
Activated B like DLBCL (B lymphoma) |
B lymphoma |
8.0e-08 |
12 |
60 |
20 |
30 |
245 |
Adenocarcinoma (Liver cancer) |
Liver cancer |
2.3e-07 |
35 |
81.3 |
43 |
97 |
207 |
Cancer (Liver cancer) |
Liver cancer |
3.6e-07 |
38 |
88.3 |
43 |
115 |
207 |
Cell line (Breast cancer) |
Breast cancer |
1.7e-06 |
15 |
57.6 |
26 |
30 |
152 |
B cells (Leukemia) |
Leukemia |
3.9e-06 |
46 |
62.1 |
74 |
62 |
141 |
B. petrussis A2 stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
9.0e-06 |
5 |
31.2 |
16 |
5 |
144 |
Breast cancer cell line (Breast cancer) |
Breast cancer |
3.5e-05 |
10 |
38.4 |
26 |
17 |
152 |
Lymphoma or lymphoma cell line (B lymphoma) |
B lymphoma |
6.8e-05 |
58 |
86.5 |
67 |
167 |
245 |
Hepatocellular carcinoma (Liver cancer) |
Liver cancer |
7.1e-05 |
33 |
76.7 |
43 |
104 |
207 |
Female hormonal cancer cell line (Breast cancer) |
Breast cancer |
8.3e-05 |
9 |
34.6 |
26 |
15 |
152 |
Invasive liver tumor (Liver cancer) |
Liver cancer |
0.0001 |
17 |
39.5 |
43 |
38 |
207 |
Bone marrow (Leukemia) |
Leukemia |
0.0002 |
20 |
27.0 |
74 |
23 |
141 |
Enriched GO annotations |
For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column). |
GO annotation |
P-value |
Hits |
Hits(%) |
Module genes |
Genes in annotation |
Genes |
G-protein coupled receptor protein signaling pathway |
3.7e-174 |
124 |
100 |
124 |
245 |
4566 |
conjugation without cellular fusion |
3.0e-94 |
79 |
63.7 |
124 |
152 |
4566 |
G-protein coupled receptor activity |
2.1e-67 |
67 |
54.0 |
124 |
170 |
4566 |
signal transducer activity |
1.2e-63 |
114 |
91.9 |
124 |
1026 |
4566 |
rhodopsin-like receptor activity |
4.5e-54 |
56 |
45.1 |
124 |
147 |
4566 |
transmembrane receptor activity |
3.0e-48 |
77 |
62.0 |
124 |
448 |
4566 |
receptor activity |
1.5e-40 |
78 |
62.9 |
124 |
582 |
4566 |
cell surface receptor linked signal transduction |
8.1e-40 |
57 |
45.9 |
124 |
259 |
4566 |
sensory perception |
1.1e-38 |
82 |
66.1 |
124 |
700 |
4566 |
chemosensory perception |
2.3e-36 |
79 |
63.7 |
124 |
682 |
4566 |
signal transduction |
8.0e-34 |
83 |
66.9 |
124 |
831 |
4566 |
cell communication |
2.2e-29 |
86 |
69.3 |
124 |
1030 |
4566 |
peptide receptor activity |
5.6e-29 |
27 |
21.7 |
124 |
55 |
4566 |
peptide receptor activity\, G-protein coupled |
3.6e-28 |
27 |
21.7 |
124 |
58 |
4566 |
response to abiotic stimulus |
5.2e-26 |
89 |
71.7 |
124 |
1228 |
4566 |
G-protein signaling\, coupled to IP3 second messenger (phospholipase C activating) |
2.0e-24 |
23 |
18.5 |
124 |
48 |
4566 |
integral to plasma membrane |
1.1e-21 |
60 |
48.3 |
124 |
612 |
4566 |
neuropeptide signaling pathway |
1.3e-20 |
18 |
14.5 |
124 |
33 |
4566 |
taxis |
3.1e-20 |
24 |
19.3 |
124 |
76 |
4566 |
chemotaxis |
2.2e-19 |
23 |
18.5 |
124 |
73 |
4566 |
energy taxis |
3.1e-19 |
23 |
18.5 |
124 |
74 |
4566 |
G-protein signaling\, coupled to cAMP nucleotide second messenger |
7.1e-19 |
18 |
14.5 |
124 |
39 |
4566 |
glutamate receptor activity |
3.7e-18 |
18 |
14.5 |
124 |
42 |
4566 |
G-protein signaling\, coupled to cyclic nucleotide second messenger |
5.2e-18 |
20 |
16.1 |
124 |
57 |
4566 |
cytosolic calcium ion concentration elevation |
8.8e-17 |
14 |
11.2 |
124 |
24 |
4566 |
cAMP-mediated signaling |
2.8e-16 |
15 |
12.0 |
124 |
31 |
4566 |
inflammatory response |
3.2e-15 |
23 |
18.5 |
124 |
108 |
4566 |
G-protein signaling\, adenylate cyclase inhibiting pathway |
1.4e-14 |
11 |
8.8 |
124 |
16 |
4566 |
thermoregulation |
2.0e-14 |
22 |
17.7 |
124 |
105 |
4566 |
G-protein chemoattractant receptor activity |
1.0e-11 |
9 |
7.2 |
124 |
14 |
4566 |
nucleotide receptor activity |
2.6e-11 |
9 |
7.2 |
124 |
15 |
4566 |
response to starvation |
6.1e-10 |
8 |
6.4 |
124 |
14 |
4566 |
intracellular signaling cascade |
7.2e-10 |
30 |
24.1 |
124 |
319 |
4566 |
negative regulation of adenylate cyclase activity |
1.0e-09 |
7 |
5.6 |
124 |
10 |
4566 |
synaptic transmission |
1.1e-09 |
18 |
14.5 |
124 |
116 |
4566 |
feeding behavior |
1.2e-09 |
8 |
6.4 |
124 |
15 |
4566 |
chemokine binding |
2.7e-09 |
7 |
5.6 |
124 |
11 |
4566 |
regulation of G-protein coupled receptor protein signaling pathway |
2.7e-09 |
7 |
5.6 |
124 |
11 |
4566 |
protein kinase C activation |
9.5e-09 |
6 |
4.8 |
124 |
8 |
4566 |
vesicle-mediated transport |
4.0e-08 |
21 |
16.9 |
124 |
196 |
4566 |
response to biotic stimulus |
6.1e-08 |
39 |
31.4 |
124 |
600 |
4566 |
phosphatidylinositol-4\,5-bisphosphate hydrolysis |
6.8e-08 |
6 |
4.8 |
124 |
10 |
4566 |
phospholipase C activation |
6.8e-08 |
6 |
4.8 |
124 |
10 |
4566 |
heterotrimeric G-protein GTPase\, alpha-subunit |
1.4e-07 |
6 |
4.8 |
124 |
11 |
4566 |
chemokine receptor binding |
2.3e-07 |
9 |
7.2 |
124 |
35 |
4566 |
MAPKKK cascade (osmolarity sensing) |
7.7e-07 |
7 |
5.6 |
124 |
21 |
4566 |
receptor binding |
9.2e-07 |
21 |
16.9 |
124 |
235 |
4566 |
invasive growth |
1.4e-06 |
6 |
4.8 |
124 |
15 |
4566 |
response to extracellular stimulus |
1.9e-06 |
32 |
25.8 |
124 |
500 |
4566 |
MAPKKK cascade |
2.9e-06 |
7 |
5.6 |
124 |
25 |
4566 |
coreceptor activity |
3.0e-06 |
5 |
4.0 |
124 |
10 |
4566 |
two-component signal transduction system (phosphorelay) |
3.9e-06 |
7 |
5.6 |
124 |
26 |
4566 |
cellular morphogenesis |
7.2e-06 |
6 |
4.8 |
124 |
19 |
4566 |
neuropeptide receptor activity |
7.4e-06 |
4 |
3.2 |
124 |
6 |
4566 |
prostaglandin receptor activity |
7.4e-06 |
4 |
3.2 |
124 |
6 |
4566 |
activation of MAPK |
9.2e-06 |
5 |
4.0 |
124 |
12 |
4566 |
metabotropic glutamate\, GABA-B-like receptor activity |
9.2e-06 |
5 |
4.0 |
124 |
12 |
4566 |
response to stress |
1.2e-05 |
41 |
33.0 |
124 |
792 |
4566 |
neuropeptide hormone activity |
1.4e-05 |
5 |
4.0 |
124 |
13 |
4566 |
cell motility |
4.5e-05 |
12 |
9.6 |
124 |
113 |
4566 |
cellular defense response |
4.8e-05 |
8 |
6.4 |
124 |
50 |
4566 |
secretion |
6.7e-05 |
18 |
14.5 |
124 |
240 |
4566 |
gamma-aminobutyric acid signaling pathway |
9.5e-05 |
4 |
3.2 |
124 |
10 |
4566 |
perception of mechanical stimulus |
9.5e-05 |
4 |
3.2 |
124 |
10 |
4566 |